Leuprex 3

Leuprorelin, the active ingredient in Leuprex 3, is a GnRH agonist presented as a formulation for subcutaneous use. It is employed to suppress sex hormone production in conditions such as prostate cancer, breast cancer, endometriosis, uterine fibroids, and precocious puberty.

GNH USA supplies Leuprex 3 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant distribution across global markets.

Leuprex 3, a GnRH agonist, is used in hormone‑dependent conditions to reduce sex hormone levels.

- Prostate cancer: reduces tumor growth by suppressing testosterone production. - Breast cancer: lowers estrogen levels to inhibit tumor progression. - Endometriosis: induces amenorrhea and reduces ectopic endometrial tissue activity. - Uterine fibroids: shrinks fibroid size by decreasing ovarian hormone stimulation. - Precocious puberty: halts early sexual development by blocking gonadotropin release.

Leuprex 3 may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Injection site reactions - Headache - Fatigue

Serious or Rare Side Effects: - Cardiovascular events such as myocardial infarction - Severe allergic reactions (anaphylaxis) - Bone fractures due to osteoporosis

Before prescribing Leuprex 3, clinicians should consider several safety precautions.

- Pregnancy: avoid use as it may affect fetal development. - Breastfeeding: not recommended because drug may be excreted in milk. - Cardiovascular disease: assess risk before initiating therapy. - Bone health: monitor bone mineral density and consider protective agents. - Concomitant hormone therapy: review for potential antagonistic effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprex 3 can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with estrogen‑containing hormonal therapy may counteract the drug’s suppressive effect. - Combination with other GnRH analogues can cause excessive hormone suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers may alter leuprorelin plasma levels. - Anticoagulants: hormonal changes may increase bleeding risk. - Bone‑protective agents (bisphosphonates, denosumab) may be needed to mitigate osteoporosis.